Group items tagged

Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma (HCC), according to a study scheduled for presentation at The Liver Meeting, held by the American Association for the Study of Liver Diseases from Oct. 20 to 24 in Washington, D.C. Teng-Yu Lee, M.D., Ph.D., from Taichung Veterans General Hospital in Taiwan, and colleagues used data from Taiwan's National Health Insurance Research Database from 1998 to 2012. Patients with non-hepatitis B infections were excluded, as were those with HCC before the follow-up index dates. A total of 1,553 patients who continuously received daily aspirin ≥90 days were randomly matched (1-to-4 ratio) with 6,212 patients who never received anti-platelet therapy based on baseline characteristics, the index date, and nucelos(t)ide analogue (NA) use during follow-up. The researchers found that the cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group in five years (2.86 percent versus 5.59 percent). Aspirin therapy was independently associated with a reduced HCC risk (hazard ratio [HR], 0.63) in a multivariable regression analysis. An increased HCC risk was independently associated with older age (HR, 1.03 per year), male gender (HR, 2.65), cirrhosis (HR, 1.89), and diabetes mellitus (HR, 1.51). NA (HR, 0.57) and statin (HR, 0.57) use were associated with a decreased HCC risk.

For patients with stage 4 or 5 chronic kidney disease and hepatitis C virus (HCV) infection, 12 weeks of treatment with glecaprevir and pibrentasvir results in a high rate of sustained virologic response, according to a study published online Oct. 11 in the New England Journal of Medicine. Edward Gane, M.D., from Auckland City Hospital in New Zealand, and colleagues conducted a multicenter trial to examine the efficacy and safety of combination treatment with the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults with HCV infection and compensated liver disease with severe renal impairment, dependence on dialysis, or both. Participants had stage 4 or 5 chronic kidney disease. One hundred four patients were enrolled in the trial. The researchers found that the sustained virologic response rate was 98 percent. During treatment, none of the patients had virologic failure, and none had a virologic relapse after the end of treatment. Pruritus, fatigue, and nausea were reported in at least 10 percent of the patients. Twenty-four percent of the patients reported serious adverse events. Because of adverse events, four patients discontinued the trial treatment prematurely; three of these had sustained virologic response

Dual-graft (DG) adult living donor liver transplantation (ALDLT) with ABO-incompatible (ABOi) and ABO-compatible (ABOc) graft combination is associated with high rates of graft survival, with no significant difference for ABOi and ABOc grafts, according to research published online July 31 in the American Journal of Transplantation. Jae Hyun Kwon, M.D., from the University of Ulsan College of Medicine in Seoul, South Korea, and colleagues conducted a retrospective review of medical records of patients who underwent ABOi DG ALDLT between 2008 and 2014. The authors also assessed the graft regeneration rate using computed tomography volumetric analysis. During a mean follow-up of 57.0 ± 22.4 months, the researchers found that the one-, three-, and five-year patient survival rate was 96.4 percent. The rate of graft survival at one-, three-, and five-years was 96.4, 94.2, and 92.0 percent, respectively; ABOc and ABOi grafts did not differ significantly (P = 0.145). No significant differences were seen between ABOc and ABOi grafts in the biliary complication rate (P = 0.195). There was no significant difference in regeneration rates for ABOi and ABOc grafts. "DG ALDLT with ABOi and ABOc graft combination seems to be a feasible option for expanding the donor pool without additional donor risks," the authors write.

American Educational Institute (AEI) Medical-Dental-Legal Update is organized by American Educational Institute (AEI) and will be held during Oct 02, 2017 - Apr 27, 2018 at Grand Wailea Resort, Maui, Hawaii, United States of America. The target audience for this medical event is Dentists. This CME Conference has been approved for a maximum of 20 AMA PRA Category 1 Credits. Conference Description : You practice in a dynamic and challenging environment. While keeping clinically current is imperative, it isn't enough. You must also acquire the skills necessary to navigate a professional liability minefield, manage a more effective and efficient practice, and navigate a maze of healthcare laws and regulations. The 2017-18 Medical-Dental-Legal Update Update is designed to assist you in that endeavor. The course, offered weekly in 32 enviable destinations, is a unique, 20-hour survey of the intersection of medicine and law as well as selected clinical topics. Produced in state-of-the-art production studios with broadcast-grade, HD digital technology. This Conference offers vital instruction from national experts in the fields of law, medicine, dentistry, asset protection, revenue cycle management and practice management. And their presentations include discussions ranging from domestic violence, payment receipt optimization, medical malpractice, fraud and abuse, and optimizing retirement and benefit plan structures, to the oral-systemic connection, medical errors, Hepatitis B & C, neurology and cardiovascular fitness. The Update is presented in a structured classroom setting affording you the opportunity for dialogue with your medical, dental and legal colleagues, and through September 28, 2018, you will have over 900 opportu­nities to attend at your choice of 30 premier sun and ski resorts - virtually any week you choose. Conference Objectives are: * Recommend preventive lifestyle behaviors and protective pharmacothe­rapy. * Assess the appropriate­ness of th

American Educational Institute (AEI) Medical-Dental-Legal Update is organized by American Educational Institute (AEI) and will be held during Oct 02, 2017 - Sep 28, 2018 at Dickenson Square, Maui, Hawaii, United States of America. The target audience for this medical event is Dentists. This CME Conference has been approved for a maximum of 20 AMA PRA Category 1 Credits. Conference Description : You practice in a dynamic and challenging environment. While keeping clinically current is imperative, it isn't enough. You must also acquire the skills necessary to navigate a professional liability minefield, manage a more effective and efficient practice, and navigate a maze of healthcare laws and regulations. The 2017-18 Medical-Dental-Legal Update Update is designed to assist you in that endeavor. The course, offered weekly in 32 enviable destinations, is a unique, 20-hour survey of the intersection of medicine and law as well as selected clinical topics. Produced in state-of-the-art production studios with broadcast-grade, HD digital technology. This Conference offers vital instruction from national experts in the fields of law, medicine, dentistry, asset protection, revenue cycle management and practice management. And their presentations include discussions ranging from domestic violence, payment receipt optimization, medical malpractice, fraud and abuse, and optimizing retirement and benefit plan structures, to the oral-systemic connection, medical errors, Hepatitis B & C, neurology and cardiovascular fitness. Conference Objectives are: * Recommend preventive lifestyle behaviors and protective pharmacothe­rapy. * Assess the appropriate­ness of the direct patient care model for your practice * Utilize a variety of clinically relevant but relatively unknown treatments. * Better recognize and respond to victims of child violence. * Better understand and deal with medical malpractice litigation. * More effectively reduce practice risk and protect assets exposed t